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Abstract
Whether the level of education is associated with anticoagulation quality and clinical out-
comes in patients with acute venous thromboembolism (VTE) is uncertain. We thus aimed
to investigate the association between educational level and anticoagulation quality and
clinical outcomes in elderly patients with acute VTE. We studied 817 patients aged65
years with acute VTE from a Swiss prospective multicenter cohort study (09/2009-12/
2013). We defined three educational levels: 1) less than high school, 2) high school, and 3)
post-secondary degree. The primary outcome was the anticoagulation quality, expressed
as the percentage of time spent in the therapeutic INR range (TTR). Secondary outcomes
were the time to a first recurrent VTE and major bleeding. We adjusted for potential con-
founders and periods of anticoagulation. Overall, 56% of patients had less than high school,
25% a high school degree, and 18% a post-secondary degree. The mean percentage of
TTR was similar across educational levels (less than high school, 61%; high school, 64%;
and post-secondary, 63%; P = 0.36). Within three years of follow-up, patients with less than
high school, high school, and a post-secondary degree had a cumulative incidence of recur-
rent VTE of 14.2%, 12.9%, and 16.4%, and a cumulative incidence of major bleeding of
13.3%, 15.1%, and 15.4%, respectively. After adjustment, educational level was neither
associated with anticoagulation quality nor with recurrent VTE or major bleeding. In elderly
patients with VTE, we did not find an association between educational level and anticoagu-
lation quality or clinical outcomes.
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Introduction
Given the narrow therapeutic range of vitamin K antagonists, a strict adherence to anticoagu-
lant therapy is important in the management of venous thromboembolism (VTE). Supra-ther-
apeutic anticoagulation, defined as an international normalized ratio (INR)>3.0, increases the
risk of bleeding, whereas sub-therapeutic anticoagulation (INR<2.0) may increase the risk of
recurrent VTE [1]. Socioeconomic factors, such as poverty or homelessness, were found to be
associated with lower adherence to anticoagulation therapy [2].
The educational level, defined as the highest level of schooling reached, is an important
socioeconomic factor and has substantial health consequences [3]. A low educational level con-
tinues to increase the risk of adverse health effects even among the elderly [4]. Although
patients with a lower educational level are more likely to have limited language proficiency,
health literacy, and lower drug adherence and warfarin knowledge scores [5–9], whether edu-
cational level is associated with anticoagulation quality in patients with VTE is uncertain. Prior
studies examining this question were limited by a cross-sectional design [10, 11] or a small
sample size [11–14], did not focus on patients with VTE [10–14], or assessed anticoagulation
quality indirectly using self-reported drug compliance or electronic medication monitoring
systems rather than the time spent in therapeutic INR range (TTR) [11, 14].
According to population-based registries, patients with a lower educational level appear to
have an increased overall risk of VTE [15, 16]. However, whether a lower education is associ-
ated with recurrent VTE or anticoagulation-related bleeding in patients with acute VTE is
unknown. To fill these gaps of knowledge, we evaluated the association between educational
level and the quality of anticoagulation in a prospective multicenter cohort of elderly patients
with acute VTE. We also examined whether the educational level was associated with recurrent
VTE or major bleeding.
Methods
Cohort sample
The study was conducted between September 2009 and December 2013 as part of a prospec-
tive, multicenter cohort study (SWITCO65+) to asses long-term medical outcomes and quality
of life in consecutive in- and outpatients aged 65 years or older with acute symptomatic, objec-
tively confirmed VTE from all five Swiss university and four high-volume non-university hos-
pitals [17]. The patient enrolment phase ended in March 2012 and patients were followed-up
until December 2013. VTE comprised proximal and distal deep vein thrombosis (DVT) and/or
pulmonary embolism (PE). Exclusion criteria were catheter-related thrombosis, thrombosis at
a different site than lower limb, insufficient German or French-speaking ability, impossibility
to follow up (i.e., terminal illness), an inability to provide informed consent (i.e., severe demen-
tia), or previous enrollment in the cohort. The detailed study methods, including eligibility cri-
teria and exact definitions of DVT and PE, were published previously [17]. The Institutional
Review Board at each participating center approved the study and patients gave written con-
sent to participation. The approving ethic committees were the “Commission cantonale d’éthi-
que de la recherche sur l’être humain Vaud” (site of Lausanne), “Commission cantonale
d'éthique de la recherche Genève” (site of Geneva), “Kantonale Ethikkommission Bern” (site of
Bern), “Kantonale Ethikkommission Zürich” (site of Zurich), “Ethikkommission Nordwest-
und Zentralschweiz” (sites of Basel, Lucerne and Baden), “Ethikkommission des Kantons
Thurgau” (site of Frauenfeld) and “Ethikkommission des Kan- tons St. Gallen” (site of
St. Gallen). For the present study, we considered all patients of the original cohort who were
treated with vitamin K antagonists within 30 days of VTE diagnosis.
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Baseline data collection
For all enrolled patients, trained study nurses prospectively collected information about base-
line demographics such as age, gender, living status (living at home with another person or
alone, or living in a nursing home), and self-reported educational level. Additional data collec-
tion included smoking status, body mass index, average weekly alcohol consumption, recent
major surgery, comorbid conditions (active cancer, arterial hypertension, chronic heart failure,
diabetes mellitus, cerebrovascular disease, chronic liver disease, chronic renal failure, inflam-
matory bowel disease, history of VTE or major bleeding), localization of index VTE (DVT
only, PE only, or both), type of VTE (provoked, unprovoked, or cancer-related), routine labo-
ratory findings (hemoglobin, platelet count), risk of falls, concomitant antiplatelet therapy or
non-steroidal anti-inflammatory drugs, polypharmacy. The risk of falls was assessed using two
validated screening questions: 1) did you fall during the last year? and 2) did you notice any
problem with gait, balance, or mobility [18]? Patients who answered yes to at least one screen-
ing question were considered to be at high risk of falls. Polypharmacy was defined as the pre-
scription of more than four drugs, including St. John’s wort, at the time of the index VTE event
[19]. The intake of vitamins or alternative medicine treatments was not considered.
Level of education
Study nurses assessed the patient’s self-reported level of education at baseline. We defined
three educational levels: 1) less than high school education (9 years of schooling completed),
2) high school degree (high school completed), or 3) post-secondary degree (diploma from a
university or an equivalent institution), as done previously [15, 16].
Anticoagulation management
Patients were treated with Acenocoumarol and Phenprocoumone, the two vitamin K antago-
nists available in Switzerland. Patients received discharge instructions and educational mea-
sures on anticoagulation by their managing physicians. After discharge, anticoagulation was
managed by primary care physicians who determined the frequency of INR measurements on
an individual basis.
Study outcomes
The primary outcome of this study was the quality of anticoagulation, expressed as the percent-
age of time spent in the therapeutic range (TTR) of the INR (2.0–3.0) according to the Rosen-
daal method [20]. Secondary outcomes were clinical events, i.e. the time to a first recurrent
VTE and major bleeding. Recurrent VTE was defined as a new or recurrent, fatal or non-fatal,
symptomatic, and objectively confirmed PE or DVT, as previously described [17]. We defined
major bleeding as a fatal bleeding, a symptomatic bleeding in a critical organ (intracranial,
intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with com-
partment syndrome), a bleeding with a reduction of hemoglobin20 g/l, or a bleeding leading
to the transfusion of2 units of packed red blood cells [21].
Follow-up included one telephone interview and two face-to-face evaluations during the
first year of study participation and then semi-annual contacts, alternating between face to-
face-evaluations and telephone calls as well as periodic hospital chart reviews. As part of the
follow-up interview/visits, study nurses obtained information about the date and type of VTE
recurrence, bleeding events, and death. We also collected INR values throughout follow-up. A
committee of three blinded clinical experts adjudicated all outcomes. The committee classified
the cause of all deaths as definitely due to PE (i.e., confirmed by autopsy or death followed a
Educational Level and VTE
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clinically severe PE), possibly due to PE (i.e., death in a patient who died suddenly or unexpect-
edly), due to bleeding, or due to another cause. Death was judged to be bleeding-related if it fol-
lowed an intracranial hemorrhage or a bleeding episode leading to hemodynamic deterioration
[22]. Final classifications were made on the basis of the full consensus of this committee.
Statistical analysis
We compared patient baseline characteristics by educational level using the chi-squared and
Kruskal-Wallis rank tests as appropriate. We compared the percentage of time spent within
one of three specified INR ranges (<2.0, 2.0–3.0,>3.0) across educational levels using analysis
of variance and adjusted regression models, excluding the first seven treatment days [20]. We
compared the cumulative incidence of recurrent VTE and major bleeding by educational level
using Kaplan-Meier analysis and the log rank test.
We examined the association between educational level and the TTR using linear regression
models, adjusting for known risk factors of poor anticoagulation quality, including age, female
gender, living status, body mass index, self-reported average weekly alcohol consumption
(expressed in standard glasses), smoking status, chronic liver disease, chronic heart failure, dia-
betes mellitus, active cancer, and polypharmacy [23–25].
We examined the association between educational level and time to first recurrent VTE and
major bleeding using competing risk regression models according to Fine and Gray, accounting
for overall death as a competing event [26]. The strength of the association between the educa-
tional level and clinical outcomes in the Fine–Gray model is reflected by the sub-hazard ratio
(SHR), which is the ratio of hazards associated with the cumulative incidence function in the
presence of a competing risk. For recurrent VTE, we adjusted for variables that were previously
shown to be associated with recurrent VTE, including age, gender, body mass index, localiza-
tion of the index VTE (PE with or without concomitant DVT, proximal DVT only, distal DVT
only), type of VTE (provoked, unprovoked, or cancer-related), history of prior VTE, inflamma-
tory bowel disease, and periods of anticoagulation as a time-varying covariate [27–34]. For
major bleeding, we adjusted for variables that were previously associated with anticoagulation-
related bleeding complications, including age, gender, self-reported average weekly alcohol
consumption (expressed in standard glasses), overt pulmonary embolism, history of major
bleeding, recent major surgery, cerebrovascular disease, chronic heart failure, diabetes mellitus,
arterial hypertension, active cancer, chronic liver disease, chronic renal disease, risk of falls,
polypharmacy, concomitant antiplatelet therapy, anemia, low platelet count, and periods of
anticoagulation as a time-varying covariate [35–43].
We assumed missing values (see Table 1) in covariates used for adjustment to be normal or
absent. All analyses were performed using Stata 14.0.
Results
Study sample
Of the 1003 patients initially enrolled in the cohort [17], we excluded 186 patients, mainly
patients with no initial oral anticoagulation (N = 132), leaving a final study sample of 817
patients with acute VTE (Fig 1). Excluded patients were more likely to be current or past smok-
ers (56% vs. 47%, P = 0.01) and to have a high risk of falls (53% vs. 44%, P = 0.021), had a lower
body mass index (median 25 vs. 27, P<0.001), had less often an unprovoked index VTE (24%
vs.68%, P<0.001), and had more often active cancer (57% vs. 9%, P<0.001), a history of major
bleeding (15% vs. 9%, P = 0.026), anemia (64% vs. 34%, P<0.001), and polypharmacy (58% vs.
49%, P = 0.016) than analyzed patients. Because direct oral anticoagulants were not yet
Educational Level and VTE
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Table 1. Patient baseline characteristics by educational level.
Less than high school (N = 460) High school (N = 206) Post-secondary (N = 151)
Characteristica n (%) or median (interquartile range) P-value
Age, years 75 (69–82) 75 (69–79) 74 (69–81) 0.42
Female gender 242 (53) 98 (48) 41 (27) <0.001
Living status 0.14
Living at home with someone else 274 (60) 142 (69) 98 (65)
Living at home alone 174 (38) 58 (28) 51 (34)
Living in a nursing home 12 (3) 6 (3) 2 (1)
Localization of index VTE 0.79
PE (with/without DVT) 323 (70) 149 (72) 111(74)
Proximal DVT 106 (23) 41 (20) 32 (21)
Distal DVT only 31 (7) 16 (8) 8 (5)
Type of index VTE
Provokedb 108 (23) 42 (20) 34 (23) 0.68
Unprovokedc 317 (69) 136 (66) 103 (68) 0.76
Cancer-relatedd 35 (8) 28 (14) 14 (9) 0.05
Arterial hypertension 298 (65) 136 (66) 92 (61) 0.59
Diabetes mellitus 72(16) 32 (16) 24 (16) 1.0
Smoking status 0.49
Current smoker 29 (6) 14 (7) 13 (9)
Past smoker 177 (39) 80 (39) 67 (44)
Never smoker 245 (55) 112 (54) 71 (47)
Body mass index (kg/m2) 27.3 (24.6–30.5) 26.9 (23.9–30.2) 26.6 (23.8–29.4) 0.03
Chronic heart failuree 36 (8) 13 (6) 10 (7) 0.75
Cerebrovascular diseasef 42 (9) 20 (10) 11 (7) 0.71
Chronic pulmonary diseaseg 66 (14) 29 (14) 15 (10) 0.37
Chronic liver diseaseh 8 (2) 2 (1) 0 (0) 0.22
Chronic renal failurei 82 (18) 41 (20) 30 (20) 0.76
Inﬂammatory bowel disease 13 (3) 9 (4) 4 (3) 0.53
Prior VTE 128 (28) 67 (33) 48 (32) 0.39
History of major bleedingj 41 (9) 22 (11) 12 (8) 0.64
Standardized alcoholic drinks/weekk 1 (0–7) 2 (0–7) 3 (0–7) 0.02
High risk of fallsl 218 (47) 84 (41) 61 (40) 0.15
Less than high school (N = 460) High school (N = 206) Post-secondary (N = 151)
Characteristica n (%) or median (interquartile range) P-value
Anemiam 164 (36) 67 (33) 44 (29) 0.26
Platelet count <150 G/l 61 (13) 24 (12) 26 (17) 0.30
Serum creatinine >1.5 mg/dl 50 (11) 15 (7) 18 (12) 0.24
Antiplatelet/NSAID therapyn 160 (35) 96 (47) 64 (42) 0.01
Polypharmacyo 228 (50) 96 (47) 77 (51) 0.68
VKA therapy prior to VTE diagnosis 18 (4) 11 (5) 8 (5) 0.63
Type of initial parenteral anticoagulation <0.001
Unfractionated Heparin 153 (33) 79 (38) 49 (32)
Low molecular weight Heparin 204 (44) 101 (49) 69 (46)
Fondaparinux 97 (21) 18 (9) 23 (15)
Danaparoid 0 (0) 0 (0) 1 (1)
No parenteral anticoagulation 6 (1) 8 (4) 9 (6)
Use of inferior vena cava ﬁlter 4 (1) 1 (0) 1 (1) 0.86
(Continued)
Educational Level and VTE
PLOSONE | DOI:10.1371/journal.pone.0162108 September 8, 2016 5 / 14
authorized for treatment of acute VTE at the time of patient recruitment in Switzerland, none
of the excluded patients was treated with direct oral anticoagulants.
Analyzed patients had a median age of 75.0 years (interquartile range [IQR] 69.0–81.0), 381
(47%) were women, and 556 (68%) had unprovoked index VTE. Overall, 460 patients (56%)
had a less than high school education, 206 (25%) were high school graduates, and 151 (18%)
had a post-secondary degree (Table 1). Patients with less than a high school education were
more likely to be women and to have a higher body mass index, and were less likely to receive
antiplatelet or non-steroidal anti-inflammatory drugs. They also had a lower alcohol consump-
tion. The median follow-up period was 30 months (IQR 24–41).
Educational level and quality of anticoagulation
There was no statistically significant difference in the percentage of TTR across the three edu-
cational levels, with a mean TTR of 61% (standard deviation [SD] 23%) in the less than high
school group, 64% (SD 23%) in the high school group, and 63% (SD 21%) in the post-second-
ary group (P = 0.36, Table 2). The percentage of time above and below the therapeutic range
did not differ by educational level. After adjustment for risk factors of poor anticoagulation
control, measures of anticoagulation quality did not differ significantly between patients with
less than high school education and those with a higher educational level (Table 3).
Educational level and clinical events
Overall, 110 patients (13.5%) died during follow-up. 105 patients (12.9%) had a first recurrent
VTE and 102 (12.5%) had a first major bleeding during follow-up. The 3-year cumulative inci-
dence of recurrent VTE and major bleeding did not differ across the three educational levels
(Fig 2A and 2B). After adjustment, patients with a high school (SHR 0.95, 95% CI 0.56–1.61)
Table 1. (Continued)
Thrombolysis 14 (3) 6 (3) 5 (3) 0.98
Thromboembolectomy 0 (0) 0 (0) 2 (1) 0.01
VTE, venous thromboembolism; PE, pulmonary embolism; DVT, deep vein thrombosis; NSAID, non-steroidal anti-inﬂammatory drug; VKA, vitamin K
antagonists.
aData were missing for anemia (7%), platelet count (7%), and creatinine (8%).
bMajor surgery, estrogen therapy, immobilization (fracture or cast of the lower extremity, bed rest >72 hours, or voyage in sitting position for >6 hours) during
the last 3 months before index VTE.
cAbsence of major surgery, estrogen therapy, immobilization, or active cancer during the last 3 months before index VT.
dCancer requiring surgery, chemotherapy, radiotherapy, or palliative care during the last 3 months before index VT.
eSystolic or diastolic heart failure, left or right heart failure, forward or backward heart failure, or a known left ventricular ejection fraction of <40%.
fHistory of ischemic or hemorrhagic stroke with hemiparesis, hemiplegia, or paraplegia at the time of screening.
gChronic obstructive pulmonary disease, active asthma, lung ﬁbrosis, cystic ﬁbrosis, or bronchiectasis.
hLiver cirrhosis, chronic hepatitis (B, C, autoimmune, etc.), chronic liver failure or hemochromatosis. Fatty liver was not considered a chronic liver disease.
iChronic renal failure requiring or not hemodialysis such as diabetic or hypertensive nephropathy, chronic glomerulonephritis, chronic interstitial nephritis,
myeloma-related nephropathy, or cystic kidney disease.
jBleeding that led to a hospital stay or transfusions.
kSelf-reported average weekly amount of alcoholic beverages during the last 12 months measured as standardized alcoholic beverages.
lSelf-reported fall during the last year or any problem with gait, balance, or mobility.
mHemoglobin <130 g/L for men and <120 g/L for women.
nUse of any antiplatelet therapy, such as aspirin, clopidogrel, prasugrel, aspirin/dipyridamol, or use of non-steroidal anti-inﬂammatory drugs.
oPrescription of >4 drugs, including St. John’s wort. The intake of vitamins or alternative medicine treatments was not considered.
doi:10.1371/journal.pone.0162108.t001
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or a post-secondary degree (SHR 1.14, 95% CI 0.68–1.92) did not have a lower risk of recurrent
VTE compared to patients with less than a high school education. Similarly, patients with a
high school (SHR 1.12, 95% CI 0.70–1.81) or a post-secondary degree (SHR 1.40, 95% CI 0.82–
2.38) did not have a lower risk of major bleeding than patients with less than high school edu-
cation (Table 4).
Discussion
In our prospective cohort of elderly patients with VTE, we found no association between the
level of education and the quality of anticoagulation, recurrent VTE, or major bleeding. Our
results are consistent with prior studies that did not demonstrate a relationship between the
level of education and anticoagulation quality in mixed samples including patients with atrial
fibrillation, VTE, and mechanical heart valves [11–13]. Although patients with a lower educa-
tional level have a limited language proficiency, a lower health literacy, and a poorer knowledge
of anticoagulation therapy [5–7], a lower level of education does not appear to translate into a
worse quality of anticoagulation or outcomes in elderly patients with VTE. Overall, our results
indicate that elderly patients with VTE who have a low educational level do not need to be spe-
cifically targeted for intensified anticoagulation-related educational measures or surveillance.
Fig 1. Patient flow chart.
doi:10.1371/journal.pone.0162108.g001
Educational Level and VTE
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In contrast to our findings, a study of elderly patients with atrial fibrillation reported that
patients with a university degree spent more time in the therapeutic INR range [10]. Similarly,
patients with atrial fibrillation who had a low income were more likely to be hospitalized for
bleeding or to experience fatal bleeds [44]. A possible explanation is that the effect of educa-
tional level and other socioeconomic factors on anticoagulation quality may be more relevant
in primary (e.g., stroke prevention in atrial fibrillation) than in secondary prevention (e.g., pre-
vention of recurrent VTE) [45].
Somewhat paradoxically, a higher educational level was associated with a decreased adher-
ence to warfarin in a prior study, possibly as a consequence of independent decision making or
reduced trust in physicians relative to less educated patients [14]. However, this study evalu-
ated the adherence to warfarin therapy, measured by electronically monitored pill bottle open-
ings, and did not determine the TTR, a more direct indicator of anticoagulation quality.
Our study has several strengths. First, our prospective cohort enrolled in- and outpatients
with acute VTE from nine Swiss university and non-university hospitals, increasing the gener-
alizability of our findings. Second, we directly and objectively assessed anticoagulation quality
using the TTR rather than self-reported or electronically measured anticoagulation compli-
ance. Third, clinical outcomes, such as recurrent VTE and major bleedings, were adjudicated
by a committee of three blinded clinical experts using pre-defined criteria, reducing the risk of
detection bias. Finally, to decrease the risk of confounding, our analyses were adjusted for the
Table 2. Anticoagulation quality by educational level.
Less than high school High school Post-secondary
Anticoagulation quality Mean percentage (SD) P-value
Time in the therapeutic range (INR 2.0–3.0) 61.4 (22.7) 64.1 (23.3) 62.8 (20.9) 0.36
Time above the therapeutic range (INR >3.0) 15.0 (16.7) 14.9 (18.3) 15.1 (16.2) 0.99
Time below the therapeutic range (INR <2.0) 23.5 (22.0) 21.0 (20.8) 22.1 (19.5) 0.35
SD, standard deviation; INR, international normalized ratio.
doi:10.1371/journal.pone.0162108.t002
Table 3. Association between educational level and anticoagulation quality.
Anticoagulation quality Adjusted differencea (95% CI) P-value
Percent
Time in the therapeutic range (INR 2.0–3.0)
Less than high school Reference -
High school 2.3 (-1.3 to 5.9) 0.21
Post-secondary 0.0 (-4.1 to 4.1) 1.0
Time above the therapeutic range (INR >3.0)
Less than high school Reference -
High school 0.1 (-2.7 to 2.9) 0.95
Post-secondary 0.6 (-2.6 to 3.8) 0.71
Time below the therapeutic range (INR <2.0)
Less than high school Reference -
High school -2.4 (-5.9 to 1.1) 0.18
Post-secondary -0.6 (-4.6 to 3.3) 0.75
INR, international normalized ratio; CI, conﬁdence interval.
aAdjusted for age, gender, living status, smoking status, body mass index, alcohol consumption, chronic liver
disease, history of heart failure, diabetes mellitus, active cancer, and polypharmacy.
doi:10.1371/journal.pone.0162108.t003
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Fig 2. Kaplan-Meier estimates of clinical outcomes by educational level. Panel A. Kaplan-Meier
estimates of a first recurrent venous thromboembolism by educational level. The 3-year cumulative incidence
of a first recurrent venous thromboembolism was 14.2%, 12.9%, and 16.4% for patients with less than high
school, high school, and a post-secondary degree, respectively (P = 0.64 by the logrank test). Panel B.
Kaplan-Meier estimates of a first major bleeding by educational level. The 3-year cumulative incidence of a
first major bleeding was 13.3%, 15.1%, and 15.4% for patients with less than high school, high school, and a
post-secondary degree, respectively (P = 0.68 by the logrank test).
doi:10.1371/journal.pone.0162108.g002
Educational Level and VTE
PLOSONE | DOI:10.1371/journal.pone.0162108 September 8, 2016 9 / 14
majority of known risk factors of poor anticoagulation control, recurrent VTE, and major
bleeding.
Our study has potential limitations. First, our study enrolled exclusively patients aged 65
years or older with acute VTE. We thus cannot generalize our results to younger patients or
those with other indications for anticoagulation. Because patients were enrolled exclusively in
hospital in- and outpatient services, healthier patients with milder forms of VTE (typically
DVT) who are managed in private practices may be underrepresented in our study. Second,
the level of education was self-reported in our study, which may have resulted in an overesti-
mation of the educational level in some patients [46]. Third, we could not evaluate other socio-
economic factors with known impact on anticoagulation quality and outcomes, such as patient
income and living area [23, 44, 47–49]. However, Swiss residents have universal health care
coverage and a good access to health care, including anticoagulant drugs and monitoring [50].
Moreover, there was no relationship between income class and access/affordability of vitamin
K antagonists in an international study [51]. Fourth, patients with severe dementia and those
with insufficient language skills were not enrolled in our cohort, both risk factors for poor
anticoagulation control [5, 23]. Thus, we cannot exclude the possibility that the inclusion of
such patients would have influenced our results. Finally, we used the TTR as a measure of
anticoagulation quality. Although it is associated with drug adherence [52, 53], other factors
such as comorbid conditions, variations in food intake or drug interactions may also have
influenced the TTR.
Conclusion
In conclusion, our results did not show an association between educational level and anticoa-
gulation quality or clinical outcomes in elderly patients with acute VTE who were treated with
vitamin K antagonists. Our findings indicate that elderly patients with VTE who have a low
educational level do not need to be specifically targeted for intensified anticoagulation-related
educational measures or surveillance.
Table 4. Association between educational level, recurrent venous thromboembolism, andmajor
bleeding.
Adjusted SHRa (95% CI) P-value
Recurrent VTE
Less than high school Reference -
High school 0.95 (0.56–1.61) 0.85
Post-secondary 1.14 (0.68–1.92) 0.62
Adjusted SHRb (95% CI) P-value
Major Bleeding
Less than high school Reference -
High school 1.12 (0.70–1.81) 0.63
Post-secondary 1.40 (0.82–2.38) 0.22
VTE, venous thromboembolism; SHR, sub-hazard ratio; CI, conﬁdence interval.
aAdjusted for age, gender, body mass index, type of the index VTE, localization of the index VTE, history of
prior VTE, inﬂammatory bowel disease, and periods of anticoagulation as a time-varying covariate.
bAdjusted for age, gender, alcohol consumption, overt pulmonary embolism, history of major bleeding, recent
major surgery, cerebrovascular disease, chronic heart failure, diabetes mellitus, arterial hypertension, active
cancer, chronic liver disease, chronic renal disease, risk of falls, polypharmacy, concomitant antiplatelet
therapy, anemia, low platelet count, and periods of anticoagulation as a time–varying covariate.
doi:10.1371/journal.pone.0162108.t004
Educational Level and VTE
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